High dose pharmacy-grade biotin is under evaluation for the treatment of adrenomyeloneuropathy. Biotin is also known as Vitamin H or Vitamin B7. This treatment could lead to a clinical improvement in walking of patients who are affected by the condition. In the phase III clinical trial, biotin is administered orally at 100mg three times a day for twenty-four months. Current treatments are limited to those which address symptoms of the condition and active physical rehabilitation.
Biotin for Adrenomyeloneuropathy without cerebral involvement
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Interventions:
Biotin (MD1003; Qizenday; Vitamin B7)
Indications:
Adrenomyeloneuropathy (AMN)
Year:
2017